285 related articles for article (PubMed ID: 17638852)
21. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
Yumeen S; Girardi M
Yale J Biol Med; 2020 Mar; 93(1):111-121. PubMed ID: 32226341
[TBL] [Abstract][Full Text] [Related]
22. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
23. Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma.
Rea B; Haun P; Emerson R; Vignali M; Farooqi M; Samimi S; Elenitsas R; Kirsch I; Bagg A
J Clin Pathol; 2018 Sep; 71(9):814-820. PubMed ID: 29636372
[TBL] [Abstract][Full Text] [Related]
24. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.
Gjerdrum LM; Woetmann A; Odum N; Burton CM; Rossen K; Skovgaard GL; Ryder LP; Ralfkiaer E
Leukemia; 2007 Dec; 21(12):2512-8. PubMed ID: 17713545
[TBL] [Abstract][Full Text] [Related]
25. Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T‑cell lymphoma.
Gibbs JD; Ma S; Kim A; Seminario-Vidal L; Sokol L; Zhang H; Zhang X; Sagatys E; Chen PL; Messina JL
Oncol Rep; 2021 Jan; 45(1):349-358. PubMed ID: 33416132
[TBL] [Abstract][Full Text] [Related]
26. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
27. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
28. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
29. Oncogenomic analysis identifies novel biomarkers for tumor stage mycosis fungoides.
Dong Z; Zhu X; Li Y; Gan L; Chen H; Zhang W; Sun J
Medicine (Baltimore); 2018 May; 97(21):e10871. PubMed ID: 29794791
[TBL] [Abstract][Full Text] [Related]
30. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
Vidulich KA; Talpur R; Bassett RL; Duvic M
Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
[TBL] [Abstract][Full Text] [Related]
32. The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL).
Litvinov IV; Netchiporouk E; Cordeiro B; Doré MA; Moreau L; Pehr K; Gilbert M; Zhou Y; Sasseville D; Kupper TS
Clin Cancer Res; 2015 Jun; 21(12):2820-9. PubMed ID: 25779945
[TBL] [Abstract][Full Text] [Related]
33. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
Fivenson DP; Hanson CA; Nickoloff BJ
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
[TBL] [Abstract][Full Text] [Related]
34. Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures.
Herrera A; Cheng A; Mimitou EP; Seffens A; George D; Bar-Natan M; Heguy A; Ruggles KV; Scher JU; Hymes K; Latkowski JA; Ødum N; Kadin ME; Ouyang Z; Geskin LJ; Smibert P; Buus TB; Koralov SB
Blood; 2021 Oct; 138(16):1456-1464. PubMed ID: 34232982
[TBL] [Abstract][Full Text] [Related]
35. p53 tumor suppressor gene mutations in transformed cutaneous T-cell lymphoma: a study of 12 cases.
Marrogi AJ; Khan MA; Vonderheid EC; Wood GS; McBurney E
J Cutan Pathol; 1999 Sep; 26(8):369-78. PubMed ID: 10551408
[TBL] [Abstract][Full Text] [Related]
36. Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Akamata K; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2012 Jul; 304(5):401-6. PubMed ID: 22526325
[TBL] [Abstract][Full Text] [Related]
37. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage.
Vasku A; Vasku JB; Necas M; Vasku V
J Biomed Biotechnol; 2010; 2010():805907. PubMed ID: 20625418
[TBL] [Abstract][Full Text] [Related]
39. Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.
Dusílková N; Bašová P; Polívka J; Kodet O; Kulvait V; Pešta M; Trněný M; Stopka T
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036928
[TBL] [Abstract][Full Text] [Related]
40. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
